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Objective
To systematically review the management of sexual
dysfunction due to central nervous system (CNS) disorders.
Patients and Methods
The review was done according to the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA)
statement. Studies were identified independently by two
reviewers using electronic searches of MEDLINE and OVID
(from January 2004 to August 2014) and hand searches of
reference lists and review articles.
Results
In patients with CNS disorders, neuro-urological assessment is
recommended for both genders before starting any treatment
for sexual dysfunction. For men, blood sexual hormones
evaluation is the main investigation performed before
phosphodiesterase type 5 inhibitors (PDE5Is) treatment,
whereas there is no consensus on routine laboratory tests for
women. PDE5Is are the first-line medical treatment for men,
with the most robust data derived from patients with spinal
cord injury assessed by validated questionnaires, mainly the
International Index of Erectile Function-15. There is no
effective medical treatment for sexual dysfunction in women.
Sacral neuromodulation for lower urinary tract dysfunction
may improve sexual dysfunction in both genders.
Conclusions
Although sexual dysfunction is a major burden for patients
with CNS disorders, high-evidence level studies are rare and
only available for PDE5Is treating erectile dysfunction.
Well-designed prospective studies are urgently needed for
both genders.
Keywords
neurogenic sexual dysfunction, neurogenic erectile
dysfunction, phosphodiesterase type 5 inhibitors
Introduction
Sexual dysfunction in patients affected by neurological
disorders has many causes. A conceptual model for sexual
problems was initially proposed to characterise three levels of
influence in patients with multiple sclerosis (MS): primary,
secondary and tertiary sexual dysfunction. Actually this model
is valid for all neurological patients and should always be
included in the diagnostic algorithm to address the
appropriate examinations and therapies for sexual dysfunction
as well. Primary sexual dysfunction results from neurological
lesions directly affecting the neural pathways subserving sexual
function. Neurological diseases affecting the cerebrum, brain
stem, spinal cord, spinal roots or peripheral nerves including
the autonomic nervous system, can alter sexual function [1,2].
Sexual dysfunction includes decreased or loss in libido, painful
or uncomfortable genital sensations (burning, tingling,
numbness), and/or altered orgasmic response in both women
and men.Women may experience decreased vaginal
lubrication and dryness, anorgasmia, and low sex drive [3,4].
Men may have difficulty achieving and/or maintaining an
erection, and diminished frequency of ejaculation [5–7].
Secondary sexual dysfunction arises as a consequence of
disability caused by poor bladder and bowel control, fatigue,
muscle weakness, spasticity, immobility, tremor, cognitive
impairment, and sensory problems. Secondary sexual
dysfunction can also be a result of non-neurological
co-morbidities, e.g. hypertension, diabetes, depression,
hypercholesterolaemia, obesity, and chronic smoking. In
addition, medications that are used for the neurological
conditions (spasticity, urinary frequency, sensory pain, etc.)
and non-neurological co-morbidities (hypertension, diabetes,
depression, etc.) can further contribute to secondary sexual
dysfunction. Tertiary sexual dysfunction is related to
psychological, social and cultural issues that affect sexual
response. These variables can include anxiety, low self-esteem,
altered marital and family roles, changes in body image, and
fear of rejection by the partner [8–11]. For each individual
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with a neurological disease, these three levels are
interconnected and may fluctuate, interfering with each other
continuously throughout life, generating or leading to a
worsening of sexual impairments. Before addressing sexual
dysfunction in a patient with a neurological disease, attitude
towards sex, sexual orientation and cultural influences should
be determined. Involvement of the patient’s partner is
recommended, if appropriate, when the quality of the
relationship and the patient/partner needs and expectations of
therapy have been assessed. Neurogenic sexual dysfunction
often severely disrupts quality of life, so that healthcare
professionals must be involved in treating an individual’s
sexual health [12,13]. In the present study, we aimed to
systematically assess the management of sexual dysfunction
due to CNS disorders.
Patients and Methods
This systematic review was performed according to the
Preferred Reporting Items for Systematic Reviews and
Meta-analysis (PRISMA) statement [14]. Two authors (M.L
and S.M.) independently searched MEDLINE and OVID using
the following terms: ‘neurogenic sexual dysfunction’ (OR)
‘neurogenic erectile dysfunction’ (OR) ‘spinal cord’, ‘multiple
sclerosis’, ‘Parkinson’s disease’, ‘stroke’, ‘epilepsy’, ‘spina bifida’
(AND) ‘sexual dysfunction’ (OR) ‘erectile dysfunction’ (OR)
‘sexual function’ (AND) ‘treatment’. Search criteria were
limited to humans, adults, and full-text English articles. All
relevant papers published in English from 2004 to 2014 were
retrieved. References of selected articles and international
guidelines were hand searched to identify additional reports.
All identified studies were screened for eligibility, in
accordance with the Cochrane Handbook for Systematic
Reviews of Interventions [15]. As this systematic review
focused on the management of sexual dysfunction due to CNS
disorders, studies on patients with peripheral neuropathy or
surgical disruption of the genital autonomic nerve supply were
excluded as were studies on fertility issues. Data extraction
was independently performed by three authors (M.L., S.M.,
G.L.) followed by crosschecking and clarification of any
differences by the senior author (G.D.P.).
Results
The flow diagram of literature searches and results is shown in
Fig. 1.We identified 302 records. In all, 256 reports were
assessed for eligibility, with 31 articles finally included in this
systematic review.
Men
The assessment of neurogenic erectile dysfunction (ED) is
based on various mandatory steps. Overall the assessment
criteria stemmed from data on patients with neurogenic ED
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Fig. 1 PRISMA flow diagram.
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treated with phosphodiesterase type 5 inhibitors (PDE5Is)
[16–21].
History
Literature reported absolute exclusion criteria to better
evaluate PDE5Is efficacy and avoid possible bias in clinical
trials: patient’s age (<18 years), concomitant neurological
illness, neurological instability (no modification of previous
neurological status in the past 6 months). Neurological
patients were excluded if not in a stable partnership
(relationship of <6 months) or were unable to attempt sexual
intercourse at least once a week.
Moreover, current treatment with nitrates or nitric oxide
donors, uncontrolled major psychiatric disorder or significant
cardiovascular disease (stroke or myocardial infarction 6
months prior absolutely excluded the possibility of starting
PDE5Is therapy) [16–21].
Conversely, the presence of co-morbidities such as diabetes or
behavioural factors (e.g. chronic smoking or alcohol abuse)
negatively influencing erectile function were not always
considered absolute contraindications but they often required
blood tests such as chemistry profile and glycated
haemoglobin to determine whether using ED therapies would
be possible [16,18,22,23].
General Assessment
Resting hypotension (systolic blood pressure <90 mmHg) or
hypertension (systolic blood pressure >170 mmHg) were
reported as exclusion criteria [16,22–24].
Uro-genital malformations and/or abnormalities, e.g. penile
curvature or severe hypospadias, were reported as exclusion
criteria for neurogenic ED treatment [22,23,25,26].
Neuro-physical Assessment
Safarinejad [20] reported neurophysiological studies, such as
pudendal nerve cortical somatosensory evoked potentials
(SEPs) and tibial nerve cortical SEPs before starting PDE5Is.
Men with spinal cord injury (SCI)
The American Spinal Injury Association (ASIA) Impairment
Scale (AIS) was used to determine the level of lesion and their
impairment grade: complete (AIS A) vs incomplete (AIS B–D)
[16–20].
Through AIS, Khorrami et al. [19] defined two groups of
lesions: the upper motoneurone (UMN) lesion referring to
injuries above the thoracic (T) levels at or above T11 and
lower MN (LMN) lesion with a level lower than T11.
Evaluation of erectile function
Some authors reported the presence of residual erectile
function only in men with SCI, evaluating reflexive erection
and/or psychological erection through the Erectile Assessment
Score (EAS), which varies from 1 (no response) to 5 (full
rigidity) [16,18,22,23].
Additionally, some authors performed intracavernosal
injection (ICI) with prostaglandin E1 (10–20 μg). Patients
unable to obtain a valid erection were excluded from PDE5Is
therapy because vascular disease was the main cause of their
ED [17,21,24].
Men with MS
All men with MS treated with PDE5Is underwent standard
neurological examinations using the Kurtzke Expanded
Disability Status Scale (EDSS). A score >6 always indicated
exclusion from PDE5Is treatment [21,24,27].
Outcome Measures for Neurogenic ED
Various outcome measures for evaluating the efficacy of
neurogenic ED treatments were used. The most frequently
used tool to specifically assess erectile function is the
International Index of Erectile Function composed of 15
questions (IIEF-15) [16,21,24,27–30].
Laboratory Investigations
Before starting therapy, most authors performed blood sexual
hormonal tests. Only patients with normal sexual hormonal
profile levels were included [16,21–26].
PDE5Is Treatment
Men with SCI (Table 1)
The clinical efficacy of sildenafil (Viagra®), vardenafil
(Levitra®), and tadalafil (Cialis®) is documented. More than
80% of patients reported trauma as the cause of their SCI
[17–19,22,23,28]. UMN lesions, the preservation of residual
erection with a score >2 on the EAS, and incomplete lesions
(AIS A vs incomplete AIS B–D) represented positive
prognostic factors for the success of PDE5Is therapy
[22,25,29].
Furthermore, the medium- and long-term efficacy of sildenafil
and tadalafil has also been documented in follow-ups of up to
10 years [16,22].
Significant statistical improvement (P < 0.01) on antegrade
ejaculation using question 9 of the IIEF-15 was detected at the
end of the clinical trials using tadalafil, vardenafil and
sildenafil [25,29,31].
In studies comparing several ED treatments, Del Popolo et al.
[17] showed that for patients with SCI tadalafil 10 mg was
more effective at 12–24 h after dosing than sildenafil 50 mg.
Moemen et al. [26] evaluated the efficacy, safety and patient
preference for different ED treatments. One 20-patient group
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was given ICI (10 μg prostaglandin E1 or 0.5 mL Trimix) for 1
month and was then shifted to sildenafil. In all, 18 patients
reached normal scores in the erectile domain of the IIEF
questionnaire composed of five questions (IIEF-5) both with
sildenafil and ICI vasoactive medication. However, 14 of 20
patients reported that they preferred sildenafil due to its easier
administration. Another group of 20 patients used a vacuum
device for 1 month, and subsequently sildenafil for 1 month.
In all, 14 patients reached a normal erectile domain score with
the vacuum device compared with 18 with sildenafil. None
from this group was satisfied by the vacuum device therapy.
Finally, Soler et al. [31] in a randomised controlled trial
comparing three different PDE5Is, showed that only the
sildenafil group had a statistically significant improvement on
the ejaculation and orgasmic domains of the IIEF-15. All three
groups showed a significant amelioration on erectile function,
satisfaction and overall satisfaction.
MS
Three sildenafil studies reported contradictory efficacy results
for patients with MS with ED. Fowler et al. [27] showed an
89% improvement rate in erectile function of the patients
selected. Lombardi et al. [21,22] using tadalafil (10 or 20 mg)
confirmed a high percentage of erectile function
enhancement, similar to the Fowler et al. study. In all, 70 of 92
patients (76.1%) who completed the 12-week treatment
reached a normal score for the IIEF-15 erectile function
domain. On the contrary, Safarinejad [20] did not find
sildenafil improved erectile function at all compared with
placebo.
Parkinson’s disease
One study of Safarinejad et al. [24] was selected according to
our criteria. In all, 116 patients in the sildenafil 100 mg group
showed a significant increase in the IIEF erectile function score
and in the percentage of ‘Yes’ responses to the Global Efficacy
Questions 2 and 3 (P < 0.001) compared with 115 patients in
the placebo group.A normal erectile function domain score
(≥26) was achieved by 56.9% and 8.7% of the patients in the
sildenafil and placebo groups, respectively (P = 0.001).
Side-Effects of PDE5Is
The most common side-effects reported in men with
neurogenic ED using PDE5Is were headache and flushing. A
low percentage of patients (<5%) discontinued treatment for
severe adverse events (AEs) correlated to the drug assumption
[16–21,24].
Other Treatments for Neurogenic ED
Drug therapy
Fampridine (also known by its chemical name of 4
aminopyridine, or 4-AP) is a specific drug used for neurogenic
spasticity in patients with chronic and incomplete SCI or MS.
One study evaluated the impact of this drug on erectile
function as well. Two domains of the IIEF-15, erectile function
(P = 0.016) and orgasmic function (P = 0.032), were
significantly improved at the end of the 12-week treatment
compared with placebo in only one (SCI-F301) of the two
identical double-blind placebo-controlled studies including
185 male patients. In all, 19 patients (16.7%) discontinued
because of severe AEs. The authors did not report data on
previous treatments for neurogenic ED [32].
Strebel et al. [33] showed disappointing results with fixed
dosages of sublingual apomorphine (3 mg). Only two of 22
patients were able to achieve valid sexual intercourse. In all, 11
patients of 22 presented side-effects, and two of them
discontinued the treatment for intolerable AEs.
Pohanka et al. [34] reported that 14 patients with advanced
Parkinson’s disease and treated with a fixed dose of 3 mg of
pergolide mesylate (Permax®) showed statistical improvement
in all IIEF-15 domains compared with baseline up to the final
12-month follow-up. Concerning the IIEF-15 erectile function
domain their mean score increased from 9.3 to 23.9 at the
final follow-up (P < 0.01).
In a prospective randomised, double-blind trial comparing the
effects of 3-months anastrazole plus testosterone (18 patients)
vs testosterone plus placebo (18 patients) in hypogonadic
epileptic men, Herzog et al. [35] found both groups
significantly increased their scores (P < 0.001) on the IIEF-5.
Perineal electrostimulation
In a study by Shafik et al. [36], 18 patients with MS with
neurogenic ED showed a substantial rise in intracavernosal
pressure during repetitive percutaneous perineal
electrostimulation lasting from 15 to 20 min (P < 0.05).
Neuromodulation
In two studies in which men with incomplete SCI were
submitted to a monolateral sacral S3 electrode implant for
their neurogenic LUTS (NLUTS) the evaluation of erectile
function was assessed at baseline and in the follow-ups after
permanent sacral neuromodulation (SNM) (Medtronic®,
Minneapolis, MN, USA) at 3 months and subsequently every 6
months after permanent SNM using the IIEF-5. Scores ≥25%,
compared with baseline, of the total IIEF-5 score indicated
remarkable enhancement on erectile function, and those
patients were considered ‘responders’. An IIEF-5 score of ≥22
represents normal erectile function. Overall, 10 of 22 men
with incomplete SCI reached and maintained a normal IIEF-5
score for >3 years at the final follow-up. However, four
patients were contralaterally re-implanted on the S3 root
during follow-up because they had lost clinical voiding and
erectile function benefits [37,38].
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On the contrary, 10 patients with complete lesions according
to the AIS had bilaterally implanted sacral S3 lead during their
shock phase to prevent neurogenic detrusor overactivity. Two
patients reported subjective amelioration on erectile function
at 6 and 24 months follow-ups, respectively [39].
Penile prosthesis
As for penile prosthesis, Zermann et al. [40] showed that
sexual intercourse was possible for 77 of 92 patients with SCIs
(83.7%) with a mean follow-up of ≈7 years for patients who
had exclusively undergone penile prosthesis for ED. Several
types of penile prosthesis were used. Only nine patients were
included pre-sildenafil release and they were ‘non-responders’.
During follow-ups, 12 patients (16.3%) did not use the
prosthesis for sexual intercourse. They complained about
instability of the erect penis or symptoms related to the
concord phenomenon.
Women
History
Women with a previous history of sexual dysfunction before
their diagnosis of neurological illness were excluded for
treatments [32,41–44].
Furthermore, a woman’s neurological status had to be stable
for ≥6 months before therapy. Only sexually active women
were included [32,41–44].
Information regarding the correlation between the use of
specific medication for their neurological disease and sexual
response was requested: ‘not related’, ‘partially related’ and
‘totally related’ [44].
Specific Neurological Assessment
The AIS assessment provided inclusion/exclusion criteria or
predictable factors for success on the basis of the level and
degree of lesion.Women with the ability to perceive T11–L2
pinprick sensations may have psychogenic genital
vasocongestion. Reflex lubrication and orgasm are more
prevalent in women with SCI who had preserved the sacral
reflex (S2–S5). For those with complete SCI of the sacral
segment, arousal and orgasm may be evoked through
stimulation of other erogenous zones above the level of lesions
such as the breasts, lips, and ears [2,45].
Neurophysiological assessment using pudendal and tibial SEPs
was reported by one author [42].
Specific Questionnaires for Assessing Primary
Sexual Dysfunction
The tools most used for neurological females were the Female
Sexual Function Index (FSFI) and the Sexual Function
Questionnaire (SFQ) (Table 2). Ta
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Specific Questionnaires for Secondary/Tertiary
Sexual Dysfunction Conditions
A number of questionnaires or other objective evaluations
(e.g. urodynamics, bladder diary) combined with specific
questionnaires for primary sexual dysfunction (e.g. FSFI) were
used to evaluate the degree of secondary factors influencing
sexual function such as: bladder, bowel function, spasticity,
and depression [32,37].
Laboratory Investigations
There is no recommended consensus about routine laboratory
tests for neurological women with sexual dysfunction.
Pregnancy was reported by some authors as an exclusion
criterion for treatment [32,42,43].
Treatment Options for Neurogenic Primary Sexual
Dysfunction in Females
There are no evidence-based therapeutic options to treat
neurological women with sexual dysfunction.
Drug therapy
Dasgupta et al. [42] in a double-blind, randomised,
placebo-controlled, crossover study investigated the positive
effects on FSFI on women with MS of sildenafil starting with
50 mg and dose adjustment (25–100 mg) for tolerability or
greater efficacy. In a double-blind placebo-controlled,
flexible-dose study with a larger cohort of females with SCIs,
Alexander et al. [41] showed a lack of clinically meaningful
benefits with sildenafil.
Two phase III, multicentre, randomised, placebo-controlled
clinical trials evaluating the use of fampridine
sustained-release tablets to treat spasticity in females with
incomplete chronic SCI did not show an amelioration in
female sexual function [32].
Gil-Nagel et al. [44] in an open, prospective, multicentre study
showed that females naïve to other anti-epileptic drugs who
initiated lamotrigine for various seizure types gained more
benefits in sexual function than women who switched to
lamotrigine from previous anti-epileptic drugs inducing the
hepatic P450 enzyme such as valproate, carbamazepine and
phentyoin.
Neuromodulation
Female patients who underwent SNM for NLUTS were also
evaluated for sexual dysfunction.
Lombardi et al. [43], in a 2-year follow-up after permanent
SNM, reported that 36.5% of females with SCI and sexual
dysfunction obtained positive effects on sexual response and
showed a remarkable concomitant improvement through the
Female Sexual Distress Scale (FSDS) questionnaire, which
measures sexually related distress.
Discussion
Many individuals with neurological disorders have impaired
sexual function that require various steps to manage
challenges, starting with an accurate assessment of the
disorder such as to tailor diagnostic investigations and
treatments to each individual. Ideally, due to the complexity of
sexual issues for neurological patients, management should be
based on multidisciplinary teamwork starting at the onset of
the neurological diagnosis and lasting for life. Scheduled
follow-ups at rehabilitation centres or in neurological
departments must comprehend sexuality issues. Therefore,
cooperation among medical specialists and other health
professionals is needed [10,46]. Although the PLISSIT
(Permission, Limited Information, Specific Suggestions, and
Intensive Therapy) model, which has health professionals
actively addressing primary, secondary, and tertiary factors,
has been successfully applied only to patients with SCI, it
could be useful for all neurological patients [2].
No data have been found about treatment of sexual
dysfunction in spina bifida adults over recent decades. One
possible reason may be the difficulty in evaluating their sexual
dysfunction and its impact on their quality of life, due also in
part to psychogenic issues. Adolescents with spina bifida
cannot have proper knowledge of sexuality because they have
never experienced it. Ideally an appropriate sex education
starting in childhood and taking into account all aspects
related to sexuality should be provided for their sexual health
[47–49].
Neuro-physiological investigations are not mandatory for
neurological patients before starting sexual dysfunction
treatment, neither to determine the severity of ED in men, nor
the type and degree of female sexual dysfunction. Moreover,
their role as predictive factors for the success of ED and
female sexual dysfunction therapies is controversial. A
hypothesis, especially relevant for women, is that several
neurophysiological tests do not examine certain aspects that
may influence female sexual response such as marital
satisfaction and marital communication, according to the
Basson et al. [50] model.
For the evaluation of blood sexual hormones, most studies on
males with neurogenic ED performed hormonal assessment
before oral treatments at baseline in order to avoid ED related
to sexual hormonal abnormalities [16,20–23,25,26].
It is well documented that neurological patients have higher
risks of hormonal modifications (mainly low levels of
testosterone) compared with the non-neurological population
[51]. Checking the hormonal status may discriminate between
possible therapies and help to decide appropriate treatment. In
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women of reproductive age, a correlation between female
sexual dysfunction and blood sexual hormonal status is not
demonstrated. However, the interaction between the CNS and
female sexual function hormones and their aetiological roles
in sexual dysfunction is complex. A strategy that includes
blood sexual hormonal assessment and subsequent hormonal
replacement is still undefined [52,53]. Both testosterone and
oestriol have been found to induce anti-inflammatory, as well
as neuroprotective effects in MS [53]. Furthermore, oestrogen
replacement probably benefits women with SCI more than it
does non-neurological patients. In fact, oestrogens prevent
osteoporosis, which is accelerated in the paralyzed and not
charged areas [52,54].
Despite those potential benefits, there are some negative
aspects to using hormonal therapies on neurological patients.
For example, females with an absence or reduction of lower
limb motility may have a high risk of thromboembolism.
Again, the use of sexual hormones on females with catamenial
epilepsy may increase the rate of seizures [1,4].
For specific neurogenic ED treatments, the existing body of
evidence suggests that the PDE5Is sildenafil, vardenafil and
tadalafil are first-line therapies for patients with SCI. However,
no information has been reported to date on the efficacy/safety
of the newer PDE5Is, avanafil and mirodenafil. Data on PDE5Is
used on other patients with neurogenic ED are partial or
missing. For male patients with Parkinson’s disease and MS,
the existing results are encouraging. For other central
neurological diseases, such as MSA and epilepsy, data seems to
suggest avoiding the use of PDE5Is as a first-line treatment for
neurogenic ED due to possible severe AEs. Hussain et al. [55]
showed that three of six patients with MSA had a severe blood
pressure plunge 1 h after sildenafil was administered (systolic
blood pressure <65 mmHg and diastolic blood pressure
<55 mmHg). Instead, information is currently insufficient to
speculate whether PDE5Is may prompt epileptic seizures in
previous non-epileptic subjects, and whether they may increase
ictal episodes in pharmacologically well-controlled seizure
disorders [55–57]. However, the choice of anti-epileptic drug
seems to be one cause of sexual dysfunction that is modifiable.
Sexual dysfunction is related to anti-epileptic drugs that induce
the hepatic P450 enzyme with a progressive increase of
sex-hormone-binding-protein levels and consequently a
decrease in free, bioavailable testosterone [58]. This may
explain the improvement in epileptic hypogonadic men on
sexual function treated with testosterone [35].
Similarly, women who had previously used anti-epileptic
drugs inducing cytochrome P450 improved sexual function
less than women who started lamotrigrine as first
monotherapy [59,60].
International guidelines recommend ICI vasoactive drugs as a
second-line treatment [2]. However, data on the efficacy of ICI
vasoactive medications for neurogenic ED are lacking
following the release of PDE5Is. Thus, no studies have been
done that exclusively include PDE5I non-responders or offer
different possible solutions as second-line treatment, alone or
combined (vacuum device, testosterone, ICI plus PDE5Is, or
PDE5Is plus testosterone).
In addition, there are no data on the daily use of PDE5Is as
penile rehabilitation for patients with a CNS disorder,
compared with those with a peripheral neurological disease, to
favour the enhancement of angiogenesis and neurogenesis of
corpora cavernosa function [61].
For specific treatments for primary female sexual dysfunction,
data are poor and controversial. Particularly, sildenafil has
been tested only on female patients with MS and SCI for
possible benefits in arousal response, although these findings
need to be confirmed with larger cohorts [41,42].
A common treatment for NLUTS for both genders is
permanent SNM. The presence and impact of this therapy on
sexual function has been evaluated by validated questionnaires
at baseline and during follow-up after permanent SNM
implantation in the medium- and long-term [43,52,56].
The objective assessment of sexual function in a treatment
approved for NLUTS is a new strategy of evaluation. Although
definitive SNM is not yet indicated for sexual dysfunction, an
objective evaluation approach regarding sexual function
should be recommended for all neurological patients
[37,38,43,62,63]. The mechanism of SNM on sexual function
is unknown, but potential direct mechanisms are possible.
Positive findings in neurological females compared with
non-neurological patients supported this thesis [43,63]. Only
continual monitoring of patients who have undergone
permanent SNM may clarify possible predictable and positive
factors on sexual dysfunction, such as stimulation setting
parameters [37,38,43,63].
A similar methodological approach was recently reported on,
which evaluated the impact of fampridine (a drug mainly used
for lower limb motility) on sexuality, using validated
questionnaires for both genders [32]. At the same time, during
primary treatment (such as PDE5Is) for sexual dysfunction,
objective assessment should also be done to evaluate impact
on secondary conditions that may interfere with therapeutic
success [64]. This holistic methodology may help to select an
appropriate and patient-tailored treatment. Based on the
multiple factors that influence neurogenic sexual dysfunction,
creating specific questionnaires for these patients is necessary.
Conclusions
Although sexual dysfunction is a major burden for patients
with CNS disorders, high-level evidence is only available on
PDE5Is that treat ED; well-designed prospective studies are
urgently needed for both genders.
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